Early Results Demonstrate Safety and Progress in SMSbiotech’s Human COPD Study
We are pleased to share a significant milestone in SMSbiotech’s ongoing human Phase 1 clinical trial for COPD, currently being conducted in Australia by Veritus Research.
As part of the study’s initial safety evaluation, the first two sentinel patients received their scheduled administrations on July 11th and July 18th, respectively. Both patients successfully completed their dosing and observation periods under close clinical supervision in accordance with the study protocol. We are pleased to report that both patients responded well, with no adverse effects or reactions related to the drug.
These encouraging results represent an important step forward in confirming the safety profile of SMSbiotech’s nebulized cell therapy platform, which will soon be applied to multiple other chronic indications. This marks a strong start to our first-in-human study and underscores the potential of our regenerative approach in addressing chronic diseases such as COPD.
We extend our sincere appreciation to our advisors, clinical partners, principal investigators, monitors, coordinators, and the research team at Veritus, as well as to our supporters for their continued confidence in SMSbiotech’s mission to advance breakthrough cell therapies.
Clinical Trial Registration:ACTRN12624001140549pRegistered with ClinicalTrials.gov and the Australian New Zealand Clinical Trials Registry (ANZCTR).
